Retinal Vein Occlusion – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Retinal Vein Occlusion – Pipeline Review, H1 2017’, provides an overview of the Retinal Vein Occlusion pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion

The report reviews pipeline therapeutics for Retinal Vein Occlusion by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Retinal Vein Occlusion therapeutics and enlists all their major and minor projects

The report assesses Retinal Vein Occlusion therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Addmedica SAS

Aerpio Therapeutics Inc

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Clearside BioMedical Inc

Formycon AG

Kala Pharmaceuticals Inc

Lupin Ltd

Mabion SA

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

ThromboGenics NV

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Retinal Vein Occlusion - Overview

Retinal Vein Occlusion - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Retinal Vein Occlusion - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Retinal Vein Occlusion - Companies Involved in Therapeutics Development

Addmedica SAS

Aerpio Therapeutics Inc

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Clearside BioMedical Inc

Formycon AG

Kala Pharmaceuticals Inc

Lupin Ltd

Mabion SA

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

ThromboGenics NV

Retinal Vein Occlusion - Drug Profiles

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aflibercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKB-9778 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bevacizumab SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

conbercept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HO-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydroxyurea - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPI-285 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LKA-651 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ocriplasmin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OTX-TKI - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Inhibit VEGF for Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranibizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

squalamine lactate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

triamcinolone acetonide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinal Vein Occlusion - Dormant Projects

Retinal Vein Occlusion - Discontinued Products

Retinal Vein Occlusion - Product Development Milestones

Featured News & Press Releases

Feb 16, 2017: Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With Retinal Vein Occlusion

Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting

Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion

Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion

Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration

Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion

Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion

Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion

Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Retinal Vein Occlusion, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Retinal Vein Occlusion – Pipeline by Addmedica SAS, H1 2017

Retinal Vein Occlusion – Pipeline by Aerpio Therapeutics Inc, H1 2017

Retinal Vein Occlusion – Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2017

Retinal Vein Occlusion – Pipeline by Clearside BioMedical Inc, H1 2017

Retinal Vein Occlusion – Pipeline by Formycon AG, H1 2017

Retinal Vein Occlusion – Pipeline by Kala Pharmaceuticals Inc, H1 2017

Retinal Vein Occlusion – Pipeline by Lupin Ltd, H1 2017

Retinal Vein Occlusion – Pipeline by Mabion SA, H1 2017

Retinal Vein Occlusion – Pipeline by Ocular Therapeutix Inc, H1 2017

Retinal Vein Occlusion – Pipeline by Ohr Pharmaceutical Inc, H1 2017

Retinal Vein Occlusion – Pipeline by ThromboGenics NV, H1 2017

Retinal Vein Occlusion – Dormant Projects, H1 2017

Retinal Vein Occlusion – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Retinal Vein Occlusion, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports